Payment overview · 2025
General Payments
$53.47
1 reported records · 1 companies
Healthcare provider profile · identity verified
John S Carr, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOGANVILLE, GA · NPI 1528257078
Verified facts
What the public records show
CMS Open Payments records show John S Carr, MD received $53.47 in general payments during 2025 across 1 reported records.
Merck Sharp & Dohme LLC accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.47 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $53.47 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 379 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 277 | 75 |
| Losartan Potassium | Losartan Potassium | 263 | 75 |
| Oxycodone Hcl | Oxycodone Hcl | 228 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 218 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 209 | 65 |
| Tramadol Hcl | Tramadol Hcl | 206 | 34 |
| Lisinopril | Lisinopril | 200 | 58 |
| Alprazolam | Alprazolam | 189 | 28 |
| Gabapentin | Gabapentin | 183 | 50 |
| Metformin Hcl | Metformin Hcl | 167 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 50 |
| Allopurinol | Allopurinol | 152 | 39 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 146 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 36 |
| Omeprazole | Omeprazole | 127 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 35 |
| Potassium Chloride | Potassium Chloride | 104 | 29 |
| Famotidine | Famotidine | 97 | 33 |
| Metformin Hcl Er | Metformin Hcl | 84 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 79 | 22 |
| Atenolol | Atenolol | 78 | 22 |
| Simvastatin | Simvastatin | 78 | 23 |
| Diazepam | Diazepam | 76 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 18 |
| Glimepiride | Glimepiride | 74 | 21 |
| Furosemide | Furosemide | 71 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 29 |
| Sertraline Hcl | Sertraline Hcl | 69 | 24 |
| Clonazepam | Clonazepam | 67 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Carvedilol | Carvedilol | 58 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Methylprednisolone | Methylprednisolone | 53 | 46 |
| Montelukast Sodium | Montelukast Sodium | 52 | 19 |
| Lovastatin | Lovastatin | 48 | 11 |
| Trazodone Hcl | Trazodone Hcl | 47 | 13 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 11 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 11 |
| Cefuroxime | Cefuroxime Axetil | 22 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 13 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 12 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.47 · 1 records | Merck Sharp & Dohme LLC | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error